Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

USD 3,000

* Required Fields

USD 3,000

PAY BY INVOICE

Be the first to review this product

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken.

Some of the key questions answered by the study include:
•     What are the current growth opportunities in biologics? What is the impact of the external environment on this market?
•     Which are the leading companies that are introducing new and innovative products in the market?
•     How do these companies intend to transform the industry paradigms in the next five years?
•     What is their strategic focus and potential for growth?
•     What are the key strategic imperatives in the biologics market?
•     What are the key strategic collaborations/partnerships and investments made by the companies to stay on the growth trajectory?

Table of Contents

1. Executive Summary
Key Findings—Analysis of Companies-2-Action
Scope and Segmentation
2. Companies-to-Action Overview
Companies to Action Value Creators
Opportunities and Threats
10 Leading Biopharma Companies to Watch
3. Key Biologics Companies Product Pipeline Analysis—Roche: Biologic Product Pipeline Analysis
Roche—Product Portfolio Overview
Roche—Key Biologic Product Pipeline
Roche SWOT Analysis
4. Amgen—Biologic Product Pipeline Analysis
Amgen—Product Portfolio Overview
Amgen—Key Biologic Product Pipeline
Amgen SWOT Analysis
5. Sanofi—Biologic Product Pipeline Analysis
Sanofi —Product Portfolio Overview
Sanofi —Key Biologic Product Pipeline
Sanofi SWOT Analysis
6. Abbvie—Biologic Product Pipeline Analysis
Abbvie —Product Portfolio Overview
Abbvie —Key Biologic Product Pipeline
Abbvie SWOT Analysis
7. Novo Nordisk—Biologic Product Pipeline Analysis
Novo Nordisk —Product Portfolio Overview
Novo Nordisk —Key Biologic Product Pipeline
Novo Nordisk SWOT Analysis
8. Merck & Co.—Biologic Product Pipeline Analysis
Merck & Co —Product Portfolio Overview
Merck & Co —Key Biologic Product Pipeline
Merck & Co SWOT Analysis
9. Pfizer—Biologic Product Pipeline Analysis
Pfizer —Product Portfolio Overview
Pfizer —Key Biologic Product Pipeline
Pfizer SWOT Analysis
10. Johnson & Johnson (JNJ)—Biologic Product Pipeline Analysis
Johnson & Johnson (JNJ)—Product Portfolio Overview
Johnson & Johnson (JNJ)—Key Biologic Product Pipeline
Johnson & Johnson (JNJ) SWOT Analysis
11. Eli Lilly—Biologic Product Pipeline Analysis
Eli Lilly—Product Portfolio Overview
Eli Lilly—Key Biologic Product Pipeline
Eli Lilly SWOT Analysis
12. GlaxoSmithKline (GSK)—Biologic Product Pipeline Analysis
GlaxoSmithKline (GSK)—Product Portfolio Overview
GlaxoSmithKline (GSK)—Key Biologic Product Pipeline
GlaxoSmithKline (GSK) SWOT Analysis
13. Growth Environment—Business Models and Competitive Playbook
Business Models in Biologics Market
Competitive Playbook—Market Share Analysis
Top 10 Biologics in the Market
Top 10 Biologics Companies
Key Merger, Acquisition & Partnership Agreements
Key Investments and Facility Expansions
14. Growth Opportunities & Companies to Action
Transformation in Industry Ecosystem
5 Major Growth Opportunities
Strategic Imperatives for Biologics Market
15. The Last Word
Conclusion—Key Take Aways
Legal Disclaimer
16. Appendix
List of Abbreviations
17. The Frost & Sullivan Story

Infographic



List of Figures & Charts

1. Biologics C2A: C2A Value Creators, Global, 2017
2. Roche: Key Marketed Biologics, Global, 2016
3. Amgen: Key Marketed Biologics, Global, 2016
4. Sanofi: Key Marketed Biologics, Global, 2016
5. Abbvie: Key Marketed Biologics, Global, 2016
6. Novo Nordisk: Key Marketed Biologics, Global, 2016
7. Global Biologics Market: Merck &Co, Key Marketed Products, Global, 2016
8. Global Biologics Market: Pfizer, Key Marketed Biologics, Global, 2016
9. Johnson & Johnson: Key Marketed Biologics, Global, 2016
10. Eli Lilly: Key Marketed Biologics, Global, 2016
11. GlaxoSmithKline: Key Marketed Biologics, Global, 2016
12. Total Biologics Market: Business Models, 2016
13. Total Biologics Market: Major Biologic Products, Global, 2016
14. Total Biologics Market: Leading Biologic Companies, Global, 2015
15. Total Biologics Market: Key Mergers and Acquisitions, Global, 2016-2017
16. Total Biologics Market: Facility Expansions and Investments, Global, 2016-17
17. Global Biologics Market: Major Growth Opportunities, Global, 2016–2021


1. Roche: Key Marketed Biologics, Global, 2016
2. Roche: Biologics by Development Phase, Global, 2017
3. Roche: Key Products in Development by Biologic Sub-segment, Global, 2017
4. Roche: Key Products in Development by Therapeutic Area, Global, 2017
5. Amgen: Key Marketed Biologics, Global, 2016
6. Amgen: Biologics by Development Phase, Global, 2017
7. Amgen: Key Products in Development by Biologic Sub-segment, Global, 2017
8. Amgen: Key Products in Development by Therapeutic Area, Global, 2017
9. Sanofi: Key Marketed Biologics, Global, 2016
10. Sanofi: Biologics by Development Phase, Global, 2017
11. Sanofi: Key Products in Development by Biologic Sub-segment, Global, 2017
12. Sanofi: Key Products in Development by Therapeutic Area, Global, 2017
13. Abbvie: Key Marketed Biologics, Global, 2016
14. Abbvie: Biologics by Development Phase, Global, 2017
15. Abbvie: Key Products in Development by Biologic Sub-segment, Global, 2017
16. Abbive: Key Products in Development by Therapeutic Area, Global, 2017
17. Novo Nordisk: Key Marketed Biologics, Global, 2016
18. Novo Nordisk: Biologics by Development Phase, Global, 2017
19. Novo Nordisk: Products in Development by Biologic Sub-segment, Global, 2017
20. Novo Nordisk: Key Products in Development by Therapeutic Area, Global, 2017
21. Merck & Co: Key Marketed Biologics, Global, 2016
22. Merck & Co: Biologics by Development Phase, Global, 2017
23. Merck & Co: Key Products in Development by Biologic Sub-segment, Global, 2017
24. Merck & Co: Key Products in Development by Therapeutic Area, Global, 2017
25. Pfizer: Key Marketed Biologics, Global, 2016
26. Pfizer: Biologics by Development Phase, Global, 2017
27. Pfizer: Products in Development by Biologic Sub-segment, Global, 2017
28. Pfizer: Key Products in Development by Therapeutic Area, Global, 2017
29. "Johnson & Johnson: Key Marketed Biologics, Global, 2016"
30. Johnson & Johnson: Biologics by Development Phase, Global, 2017
31. Johnson & Johnson: Products in Development by Biologic Sub-segment, Global, 2017
32. Johnson & Johnson: Key Products in Development by Therapeutic Area, Global, 2017
33. Eli Lilly: Key Marketed Biologics, Global, 2016
34. "Eli Lilly: Biologics by Development Phase, Global, 2017"
35. Eli Lilly: Key Products in Development by Biologic Sub-segment, Global, 2017
36. Eli Lilly: Key Products in Development by Therapeutic Area, Global, 2017
37. GlaxoSmithKline: Key Marketed Biologics, Global, 2016
38. GlaxoSmithKline: Biologics by Development Phase, Global, 2017
39. GlaxoSmithKline: Products in Development by Biologic Sub-segment, Global, 2017
40. GlaxoSmithKline: Key Products in Development by Therapeutic Area, Global, 2017
41. Global Pharmaceutical Market: Top Ten Drugs by Sales, Global, 2016
42. Total Genset Market for Water and Wastewater Treatment Plants: Revenue Breakdown by Genset Type, Global, 2016 and 2021



Keyword1
biologic
Keyword2

Keyword3
biologic

Related Research

Release Date : 16-Aug-16

Region : North America

Release Date : 31-May-2016

Region : Asia Pacific

Release Date : 29-Apr-2016

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.